Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.

about

γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor.

P2860

Q51735096-80F18259-21B8-4D55-9B6C-5D074782C48B Q55715343-1EA309CC-2B38-49B5-8E4E-CD25C37EAA9F

P2860

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.

Item

http://www.wikidata.org/entity/Q38733149

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.

@en

type

Item

label

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.

@en

prefLabel

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.

@en

P1476

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice

@en

P2093

Angel Loza Valdes

http://www.w3.org/2001/XMLSchema#string

Jay D Horton

http://www.w3.org/2001/XMLSchema#string

Jesper Gromada

http://www.w3.org/2001/XMLSchema#string

Norma Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Severe sepsis and septic shock

Molecular biology of PCSK9: its role in LDL metabolism

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

Effect of statin therapy on mortality from infection and sepsis: a meta-analysis of randomized and observational studies.

Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.

Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

P304

1661-1669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M076844

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean Mathieu Berger

P577

2017-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28600283

http://www.w3.org/2001/XMLSchema#string

P921

lipopolysaccharide

P932

5538287

http://www.w3.org/2001/XMLSchema#string

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.

about

P2860

P2860

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932